HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Paul J Kostenuik Selected Research

RANK Ligand

1/2018Selective inhibition of receptor activator of NF-κB ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction.
12/2015Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice.
5/2012Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
3/2012Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
4/2008Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.
1/2008Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
7/2007RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.
12/2005Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
10/2005RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Paul J Kostenuik Research Topics

Disease

22Bone Resorption
11/2018 - 05/2003
9Osteoporosis
10/2020 - 04/2004
4Neoplasm Metastasis (Metastasis)
09/2015 - 01/2008
4Neoplasms (Cancer)
08/2012 - 08/2005
4Postmenopausal Osteoporosis
08/2012 - 04/2009
3Metabolic Bone Diseases (Osteopenia)
12/2015 - 04/2004
3Bone Diseases (Bone Disease)
09/2015 - 02/2009
2Alveolar Bone Loss
10/2020 - 07/2007
2Prostatic Neoplasms (Prostate Cancer)
09/2015 - 08/2012
2Vascular Calcification
08/2009 - 01/2008
2Rheumatoid Arthritis
04/2008 - 12/2002
2Hypercalcemia (Milk Alkali Syndrome)
10/2007 - 08/2005
1Periodontal Diseases (Periodontal Disease)
10/2020
1Myocardial Infarction
01/2018
1Cicatrix (Scar)
01/2018
1Vitamin D Deficiency
09/2015
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
09/2015
1Breast Neoplasms (Breast Cancer)
08/2012
1Hip Fractures (Intertrochanteric Fractures)
03/2012
1Cellulitis
03/2012
1Paralysis (Palsy)
03/2012
1Eczema
03/2012
1Osteomalacia
08/2011
1Experimental Arthritis
11/2008
1Leukocytosis (Pleocytosis)
11/2008
1Disease Progression
11/2008
1Coronary Artery Disease (Coronary Atherosclerosis)
01/2008
1Metaplasia
01/2008
1Atherosclerosis
01/2008
1Vascular Diseases (Vascular Disease)
01/2008
1Periodontitis
07/2007
1Inflammation (Inflammations)
10/2005
1Arthritis (Polyarthritis)
10/2005
1Humoral Hypercalcemia Of Malignancy
08/2005
1Adenocarcinoma
08/2005
1Chronic Disease (Chronic Diseases)
04/2004

Drug/Important Bio-Agent (IBA)

14OsteoprotegerinIBA
11/2018 - 12/2002
11DenosumabFDA Link
09/2015 - 04/2008
9RANK LigandIBA
01/2018 - 10/2005
5Biomarkers (Surrogate Marker)IBA
11/2018 - 08/2005
5CytokinesIBA
01/2018 - 12/2005
4Monoclonal AntibodiesIBA
09/2011 - 02/2009
3CalciumIBA
11/2018 - 08/2009
3LigandsIBA
01/2018 - 03/2012
3Proteins (Proteins, Gene)FDA Link
05/2009 - 04/2004
2Estrogens (Estrogen)FDA Link
01/2017 - 03/2012
2Zoledronic Acid (Zometa)FDA Link
09/2015 - 08/2005
2Bone Density Conservation AgentsIBA
07/2013 - 04/2004
2Hormones (Hormone)IBA
08/2012 - 12/2005
2deoxypyridinolineIBA
08/2009 - 05/2009
2GlucocorticoidsIBA
08/2009 - 05/2009
2Anabolic AgentsIBA
04/2009 - 10/2007
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2008 - 12/2005
1Neutralizing AntibodiesIBA
10/2020
1romosozumabIBA
10/2020
1Dental Implants (Dental Implant)IBA
10/2020
1Estrogen Receptor alphaIBA
01/2017
1ElementsIBA
01/2016
1OsteocalcinIBA
12/2015
1Alkaline PhosphataseIBA
09/2015
1Collagen Type I (Type I Collagen)IBA
09/2015
1CreatinineIBA
09/2015
1collagen type I trimeric cross-linked peptideIBA
09/2015
1Fluorescent Dyes (Fluorescent Probes)IBA
07/2015
1Type A Botulinum Toxins (Botox)FDA Link
03/2012
1Cytokine Receptors (Cytokine Receptor)IBA
03/2012
1Testosterone (Sustanon)FDA Link
10/2009
1Tartrate-Resistant Acid PhosphataseIBA
05/2009
1Interleukin-6 (Interleukin 6)IBA
11/2008
1ProstaglandinsIBA
11/2008
1Prostaglandins EIBA
11/2008
1Transforming Growth Factor beta (TGF-beta)IBA
11/2008
1Caspase 3 (Caspase-3)IBA
01/2008
1Parathyroid Hormone (Parathormone)IBA
10/2007
1ImmunosorbentsIBA
09/2007
1EnzymesIBA
09/2007
1CollagenIBA
10/2005
1Diphosphonates (Bisphosphonates)IBA
08/2005
1Parathyroid Hormone-Related ProteinIBA
08/2005
1Pamidronate (Aredia)FDA LinkGeneric
08/2005

Therapy/Procedure

2Therapeutics
08/2012 - 09/2011
1Aftercare (After-Treatment)
01/2016
1Subcutaneous Injections
12/2015
1Ovariectomy (Oophorectomy)
05/2008
1Ligation
07/2007
1Intravenous Injections
05/2003